➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Colorcon
Merck
McKesson
Moodys

Last Updated: May 18, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OTEZLA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Otezla

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00521339 Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis Completed Celgene Corporation Phase 2 2007-08-01 The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
NCT00773734 Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) Completed Celgene Corporation Phase 2 2008-09-01 The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.
NCT00866359 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease Completed Celgene Corporation Phase 2 2009-10-01 The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease.
NCT01194219 Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis Active, not recruiting Celgene Corporation Phase 3 2010-09-01 This study evaluated the effects of an called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis. The purpose of this study was to test apremilast and compare its effects to placebo (an inactive substance which contains no medicine but is in the same form as the drug). This study was able to test for efficacy (improvement of signs and symptoms) and safety of apremilast in patients with moderate to severe psoriasis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Otezla

Condition Name

Condition Name for Otezla
Intervention Trials
Plaque Psoriasis 8
Psoriasis 6
Psoriatic Arthritis 5
Healthy Volunteers 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Otezla
Intervention Trials
Psoriasis 17
Arthritis 7
Arthritis, Psoriatic 6
Dermatitis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Otezla

Trials by Country

Trials by Country for Otezla
Location Trials
United States 164
Canada 37
Australia 11
Germany 5
Switzerland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Otezla
Location Trials
California 13
Florida 11
New York 8
Illinois 8
Texas 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Otezla

Clinical Trial Phase

Clinical Trial Phase for Otezla
Clinical Trial Phase Trials
Phase 4 14
Phase 3 7
Phase 2 13
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Otezla
Clinical Trial Phase Trials
Not yet recruiting 12
Recruiting 12
Completed 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Otezla

Sponsor Name

Sponsor Name for Otezla
Sponsor Trials
Celgene Corporation 18
Celgene 8
Amgen 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Otezla
Sponsor Trials
Other 37
Industry 30
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
AstraZeneca
McKesson
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.